'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Cantor Fitzgerald Sees ~4.9M Shares of Teva (TEVA) Being Bought Amid TASE Index Rebalance
November 30, 2017 12:22 PM ESTCantor Fitzgerald analyst Louise Chen weighed in on the TASE index weight re-balancing for Mylan (NYSE: MYL) and Teva (NASDAQ: TEVA) after Mylan announced it is voluntarily delisting its ordinary shares from trading on the Tel Aviv Stock Exchange... More
Teva Pharma (TEVA) Announces NEJM Publishes Data from Pivotal Phase III Trial of Fremanezumab for Preventive Treatment of Chronic Migraine
November 29, 2017 5:07 PM ESTTeva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose regimens of fremanezumab for the preventive treatment of chronic migraine (CM). These data were published online today by the New England Journal of Medicine (NEJM) and will appear in a subsequent print issue.
The burden of illness faced by those with migraine is immense and can negatively impact every facet of their lives underscoring a significant unmet... More
Notable Call Buying Activity in Teva Pharma (TEVA) Continues -Susquehanna
November 29, 2017 2:45 PM ESTSusquehanna options strategist Alison Edwards notes continued buying activity Teva Pharma (NYSE: TEVA) , as an opening investor bought 15k Jan 15 Calls, most for $1.10, creating ~750k shares to buy.
... MoreTeva Pharma (TEVA) PT Raised to $16 at Mizuho Securities on Announced Major Cost Cuts
November 29, 2017 6:45 AM ESTMizuho Securities raised its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $12.00) while maintaining a Neutral rating, following a model update fueled by conversations with management.
Analyst Irina Koffler notes a positive outlook on the shares, following conversations with management... More
